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Abstract
Background: Since Canadian drug regulatory approval of mifepristone for medical abortion in 2015 and its market
availability in January 2017, the role of pharmacists in abortion provision has changed rapidly. We sought to identify
the factors that influenced the initiation and provision of medical abortion from the perspectives of Canadian
pharmacists, bridging two frameworks — Diffusion of Innovation in Health Service Organizations and integrated
knowledge translation.
Methods: We conducted one-on-one semi-structured interviews with pharmacists residing in Canada who
intended to stock and dispense mifepristone within the first year of availability. Our data collection, analysis, and
interpretation were guided by reflexive thematic analysis and supported by an integrated knowledge translation
partnership with pharmacy stakeholders.
Results: We completed interviews with 24 participants from across Canada: 33% had stocked and 21% had
dispensed mifepristone. We found that pharmacists were willing and able to integrate medical abortion care into
their practice and that those who had initiated practice were satisfied with their dispensing experience. Our analysis
indicated that several key Diffusion of Innovation constructs impacted the uptake of mifepristone, including:
innovation (relative advantage, complexity and compatibility, technical support), system readiness (innovation-
system fit, dedicated time, resources), diffusion and dissemination (expert opinion, boundary spanners, champions,
social networks, peer opinions), implementation (external collaboration), and linkage. Participants’ experiences
suggest that integrated knowledge translation facilitated evidence-based changes to mifepristone dispensing
restrictions, and communication of those changes to front line pharmacists.
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Conclusions: We illustrate how Diffusion of Innovation and integrated knowledge translation may work together as
complimentary frameworks for implementation science research. Unlike in the USA, UK, and other highly regulated
settings globally, pharmacists in Canada are permitted to dispense mifepristone for medical abortion. We contribute
to literature that shows that mifepristone dispensed outside of hospitals, clinics, and medical offices is safe and
acceptable to both patients and prescribers. This finding is of particular importance to the current COVID-19
pandemic response and calls for continued and equitable access to abortion care in primary practice.
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Contributions to the literature
 We demonstrate how to bridge Diffusion of Innovation and
integrated knowledge translation constructs to investigate
implementation of a pharmacological intervention, using the
case of the abortion pill, mifepristone.
 Our analysis of interviews with pharmacists indicates that
diffusion of information about the medication through
organizations and champions was key to implementation.
 Integrated knowledge translation practices can leverage
communication with organizations and champions, further
facilitating implementation.
Background
Canada is one of the first pharmaceutically regulated
countries in the world to approve pharmacists’ dispensa-
tion of mifepristone, the medical abortion pill, directly
to patients [1, 2]. This task sharing between pharmacists,
as experts in medication stocking, dispensing, and coun-
selling, and prescribing healthcare providers is consid-
ered preferable for the provision of prescription
medications [3–5]. In provinces like Quebec and accord-
ing to its physician’s code of ethics, physicians cannot
stock or dispense most prescription medications, includ-
ing mifepristone, to avoid conflict of interest; only phar-
macists can [6–8]. This evidence- and ethically-based
approach stands in contrast to more restrictive first tri-
mester medical abortion regulations in the USA and UK,
where mifepristone is dispensed to patients by the
authorized prescriber [9, 10]. Safe and effective task
sharing to dispense medications is within the pharmacist
scope of practice and offers an opportunity to improve
access to care [11].
Historically, medical abortion in Canada could be pro-
vided only through off-label use of methotrexate and mi-
soprostol prescribed by physicians in private,
community, or hospital-based specific abortion clinics,
and more than 95% of abortion care was surgical [12]. In
2015, mifepristone was approved in Canada and first be-
came commercially available in January 2017 but was
subject to restrictive requirements (Table 1). These in-
cluded dispensation to patients directly by a physician
with observation of the initial mifepristone dose,
mandatory training and certification of prescribing phy-
sicians and pharmacists, and registration of prescribing
physicians and pharmacists with the manufacturer [13,
14]. By November 2017, each restriction was removed,
paving the way for pharmacists to dispense mifepristone
and providing a test-case for task sharing of medical
abortion services in routine primary care. Pharmacist at-
titudes toward participation in emergency contraception
[15] and other family planning care have been found to
be positive [4], indicating potential openness to partici-
pating in abortion care.
While pharmacists have the potential to facilitate rapid
community-based access to the medication and to
streamline reimbursement mechanisms for patients [5],
implementing new pharmaceutical therapies like medical
abortion can be a complex process. Diffusion of
Innovation theory can be a helpful framework for inves-
tigating the constellation of factors that influence real-
world implementation in pharmaceutical practice [16–
18]. The theory posits that implementing an innovation
(e.g., mifepristone) depends on its simplicity and trial-
ability, its benefits and advantages relative to what was
previously used, and its fit with adopters’ values, needs,
and tasks [19]. Implementation also depends on the abil-
ities and willingness of the adopter (e.g., pharmacists),
the size and readiness of their organizations, and the
support and resources offered by others in and outside
the health care system. Implementation efforts may exist
on a continuum from highly managed (“make it hap-
pen”) to flexible and adaptive (“let it happen”) [19]. For
systems-level challenges involving stigmatized health
services, like the implementation of mifepristone abor-
tion care in Canada, Greenhalgh and Papoutsi argue that
“ecological and social practice perspectives” like Diffu-
sion of Innovation are particularly appropriate as they
follow the logic of complex systems which are character-
ized by unpredictability, interdependencies, and self-
organization [20]. One additional strategy that can “help
it happen” and facilitate self-organization through rela-
tionships and sensemaking is integrated knowledge
translation (KT), the process of partnering with know-
ledge users at all stages of an implementation study [21].
The collaboration can include co-developing the
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research question, making shared choices about study
design, partnering to design study tools and partici-
pate in data collection, and interpreting and dissemin-
ating results together. In integrated KT, there is an
implicit understanding that knowledge users and re-
searchers bring complmentary contextual and meth-
odological expertise to the process [22]. The
continuous collaboration involved in integrated KT —
characterized by social interaction and negotiation to
enable spread of knowledge — closely reflects Green-
halgh’s “help it happen” approach to diffusion of
innovations in health care (see Figure 1).
The present research was part of a larger mixed-
methods investigation [23]. In the main study, we asked
the following questions: What are the factors that influ-
ence successful initiation and ongoing provision of med-
ical abortion services among health professionals, and
how do these relate to health policies, systems, and ser-
vices, and to abortion service access throughout Canada?
For the present analysis, we focused on the first question
involving the identification of factors that influence the
initiation and provision of medical abortion from the
perspectives of Canadian pharmacists. We demonstrate
how we operationalized two complimentary approaches
Fig. 1 A conceptual basis for knowledge spread where Diffusion of Innovation meets integrated knowledge translation. Adapted from
Greenhalgh et al. [19] and Bowen and Graham [21]





Removed requirement for observation of mifepristone ingestion. The patient can take the medication where and
when they choose.
Oct 2016
Training Removed requirement for training for pharmacists. May 2017
Training Removed requirement for training for prescribers. November
2017
Consent form Removed requirement for a manufacturer consent form to be signed by the patient. November
2017
Registration Removed requirement for registration of prescribers or pharmacists with the manufacturer. November
2017
Dispensing Mifepristone can be dispensed directly to patients by a pharmacist or prescribing health professional, rather than
the original requirement that a physician must dispense directly to the patient.
November
2017
Gestational age Mifepristone-misoprostol may be used up to 9 weeks (63 days) from last menstrual period, rather than the original
7 weeks (49 days).
November
2017
Ultrasound Removed requirement for mandatory ultrasound prior to prescribing. April 2019
Source: Munro et al. [13]
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that embrace a complexity lens — Diffusion of
Innovation theory and integrated KT.
Methods
This study was part of a national mixed-methods
programme of research designed to characterize and fa-
cilitate the implementation of mifepristone medical
abortion between 2015 and 2019 [23]. The research was
informed by an integrated KT approach premised on the
understanding that research is more relevant and useful
when knowledge users are equal partners in the work
[24, 25]. Consequently, pharmacist stakeholders were
members of the research team and contributed to study
design, recruitment, interpretation, and dissemination.
As planned with our integrated KT approach, we en-
gaged in monthly feedback meetings to exchange results
in progress to stakeholders, guided by principles of sen-
semaking [26, 27] — the process through which people
assign meaning to experience. Our sensemaking sought
to understand how mifepristone implementation un-
folded and exchange real-time insights to encourage
evidence-based practice and policy action that would fa-
cilitate implementation.
The theoretical framework that guided our study was
Diffusion of Innovation in Health Service Organizations
described by Greenhalgh and colleagues, which includes
six broad constructs representing 58 dimensions [19].
Although Diffusion of Innovation captures the inter-
dependence of individual, organizational, and contextual
factors affecting implementation, its complexities are dif-
ficult to capture in applied research [28, 29]. We there-
fore adapted Cook and colleagues’ operationalization of
the constructs, which has been applied in previous quali-
tative investigations [28, 30–34]. Our use of integrated
KT further acted to support each researcher and know-
ledge user on the team to gain a shared understanding
of this theory and co-create a study design guided by the
framework.
Participants and recruitment
Participants eligible for this study were pharmacists res-
iding in Canada who intended to stock and dispense
mifepristone within the first year of availability and
could speak English or French. Participants were re-
cruited by email from a list of pharmacists who had con-
sented to be contacted for an interview in a previous
survey circulated through the Canadian Abortion Pro-
viders Support community of practice [35]. We purpose-
fully sampled for a diversity of characteristics relevant to
participation in abortion care (e.g., previous experience
in family planning, geographic region, gender, age, tim-
ing of adoption of this new practice). We continued
sampling until we had satisfied key markers of satur-
ation: the characteristics were well-represented;
additional interviews were consistent with previous data;
no new themes were identified in analysis; and each
theme was demonstrable within the sample [36, 37].
Characteristics of participants were documented for
sampling and analysis but are not reported in the study
in order to maintain participant anonymity.
Data collection
We conducted one-on-one telephone interviews with
participants between June 2017 and February 2018,
which allowed us to characterize uptake of mifepristone
among pharmacists before and after the removal of re-
strictions on this medication in November 2017. The in-
terviews proceeded according to a semi-structured
interview guide (see Additional file 1) informed by Cook
and colleagues’ operationalization of the Diffusion of
Innovation constructs and developed and pilot tested
with an expert panel of clinicians and researchers [28].
Senior health services researchers (SM, EG) and trainees
oriented in the study procedures (CD, GL-R) conducted
the interviews, which were audio-recorded. The study
lead (SM) was a qualitative researcher while all other
team members had clinical backgrounds (family medi-
cine, obstetrics and gynaecology, public health, phar-
macy, nursing). Interviewers engaged in reflexive
practice by considering the relative status, power, and
comfort of participants throughout the data collection
process, as well as how their training and background
may influence their interpretation of the data. Partici-
pants provided verbal consent at the beginning of the
interview.
Data analysis
The interviews were transcribed, de-identified, and
assigned a numeric identifier (e.g., Participant 001). We
translated the French transcripts to English. Led by a
member of the study team with expertise in qualitative
research (SM), three trainees (NA, EW, KW) conducted
a reflexive thematic analysis of the data according to the
flexible approach described by Braun and Clarke [38–
40]. This approach was selected as it focuses on re-
searcher subjectivity and knowledge as constructed, situ-
ated, and contextual. We were not seeking a single truth
but rather multiple perspectives that capture the com-
plexity of implementation of mifepristone, consistent
with our theoretical framework, Diffusion of Innovation.
We familiarized ourselves with the data by reading the
transcripts as a whole and noting initial impressions. We
adopted a complexity standpoint and approached our
analysis with the belief that implementation is more than
the sum of its parts; it is characterized by the dynamic
interplay between elements and relationships. Thus, our
team engaged in multiple stages of analysis; we went be-
yond coding and categorization to also engage in
Munro et al. Implementation Science           (2021) 16:76 Page 4 of 13
mapping processes and relationships. Analysis of inter-
view transcripts involved four iterative steps:
1. Inductively identifying contextual codes related to
our research question;
2. Refining codes through iterative analyses that
considered patterns across participant data;
relationship among individual, organizational, and
system-level themes; conflicting themes; and the
observed relevance of themes to the research
question;
3. Identifying individual, organizational, and system
processes (including patterns, relationships, and
interactions) between the codes; and
4. Deductively mapping the results of this analysis
(codes, patterns, and relationships) to the Diffusion
of Innovation framework through iterative team-
based workshopping sessions and during manu-
script preparation.
Discrepancies that arose were resolved by consensus
among the study team. Strategies to support the rigour
of our analysis included constant comparison, audit
trails, and meetings with pharmacist stakeholders to dis-
cuss and contextualize results in progress.
Results
Participants
We conducted 24 one-on-one interviews with pharma-
cists involved in the dispensing of mifepristone medical
abortion services in Canada. All participants were volun-
teers who consented to participate and completed their
interview. On average, each interview lasted 45 min. Of
the participants, 33% had stocked and 21% dispensed
mifepristone; of the remaining participants, all but one
intended to distribute mifepristone in the future. Partici-
pants were geographically distributed, with 46% from
western provinces (British Columbia, Alberta, Saskatch-
ewan, Manitoba), 38% from central provinces (Ontario,
Quebec), and 17% from an Atlantic province or Terri-
tory (New Brunswick, Yukon).
Five broad Diffusion of Innovation constructs, com-
prising a total of 13 Diffusion of Innovation dimensions,
emerged as important to pharmacist participation in
medical abortion care (see Figure 2). These included the
innovation (relative advantage, complexity and compati-
bility, technical support), system readiness (innovation-
system fit, dedicated time and resources, power imbal-
ances), diffusion and dissemination (expert opinion,
boundary spanners, champions, social networks, peer




Relative advantage refers to the perception that the
innovation is superior to existing alternatives. Partici-
pants agreed that mifepristone carried clear advantages
related to increased reproductive choice for people seek-
ing abortion care, more equitable access for people living
Fig. 2 Determinants of diffusion of innovations in health service delivery organizations, adapted from Greenhalgh et al. [19]. Source: Norman
et al. [23]
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in rural areas without local surgical abortion care, priv-
acy and convenience for those seeking to have an abor-
tion at home, a less invasive experience than surgical
care, and greater effectiveness compared with previous
off-label medical abortion regimes. As one participant
from a western province said:
The huge thing is that most of the patients, espe-
cially if they are coming from rural areas, if any
pharmacies were there, they don’t have to travel
five, six hours to a city like this to actually have it
even done because it’s not surgical. It’s just a medi-
cation that can be dispensed. In addition, of course,
the success rate is great. It’s fairly close to sort of
the surgical component, but it doesn’t carry some of
the associated risks … Thirdly, it provides patients
not only accessibility, but a bit of privacy as well,
which is actually another thing that I think we’ll
need to discuss. Privacy and accessibility and then
the rate of success, I think, are probably the three
biggest advantages to it. (003)
The related Diffusion of Innovation dimensions of risk
and assessment of implications were relevant to how
participants viewed potential disadvantages of mifepris-
tone. A few participants raised the possibility of patients
having complications in the community, without a guar-
anteed way to follow up. Others pointed out that reim-
bursement for the cost of mifepristone was a challenge
both for patients paying out of pocket (before reim-
bursement by public and private insurance could be set-
tled) and for pharmacists stocking the medication
without a sense of consumer demand. The concern
about costs was articulated by an urban participant from
a central province who explained:
It does cost $300. From an inventory standpoint, we
can’t have shelves and shelves of it. We keep a mini-
mum stock. We haven’t been able to assess trends.
That’s what we use to stock the pharmacy. We look
at trends over weeks, over months to see how much
of this do we dispense. It’s still relatively new, and
you’ve only dispensed it to one patient. You can
only keep two boxes. From that point, it’s just lack
of data might impede on ability to stock it. (020)
Complexity and compatibility
Many participants perceived that dispensing mifepris-
tone was no different from other medications — it had
similar complexity and compatibility. The complexity of
an innovation depends on how difficult it is to use while
its compatibility relates to the degree of alignment with
system and user values, needs, and experiences. For
example, one participant from a western province
explained:
The minute we receive the prescription, it’s as simi-
lar to any other prescription. Some of the medica-
tion, we have to order for the next day, and then we
arrange for the patient to come and sit with one of
our pharmacists to talk about it. Similar to any new
medication for any other medical condition. (017)
Specific concerns about the complexity of mifepristone
mostly related to counselling, which all participants
agreed should be comprehensive. The notion that coun-
selling complicated care appeared to depend on the de-
gree to which the pharmacist felt equipped to discuss
the potentially sensitive topic of abortion. For instance,
one participant from an Atlantic province explained,
Obviously, the person who is seeking … a very sen-
sitive product, so it does require maybe a greater
level of empathy or that sort of emotional part that
goes along with it as well. Definitely, I feel it’s in the
pharmacy’s scope. I feel it’s in my scope, but I feel
like I need a higher level of kind of effort that goes
into it because there may or may not be an emo-
tional part as well. (001)
Another participant from a central province (021)
pointed out that although dispensing mifepristone might
be time-consuming, there would be a low volume of pre-
scriptions in their rural town and mifepristone would
have a limited impact on their workload and workflow.
Notably, pharmacists who had dispensed mifepristone
articulated less concern about counselling, as one par-
ticipant described,
After the first maybe two or three patients I dealt
with, it became fairly sort of standard, easy, and I
felt a lot more comfortable in terms of dispensing it.
(003)
Technical support
Participants articulated that their mifepristone practice
was supported by adequate training, namely the national
online training course (Society of Obstetricians and
Gynaecologists’ Training on Medical Abortion) that was
originally required for any pharmacist involved with
mifepristone provision. Overall, participants felt that the
course had an appropriate level of difficulty and was
consistent with other training they had completed. Some
participants noted that the length of the training was a
barrier and that a course specifically designed for phar-
macists would be more professionally relevant. As one
participant from Quebec said, “Three and a half hours is
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far too long for the impact it will have on our practice.
On the other hand, if there was a specific module on
pharmacology, maybe we could use it” (Q05). Others
mentioned that the limitation of the free, unaccredited
version of the training programme, versus the paid
version providing continuing education credits, was a
potential barrier.
Participants described drawing on various resources
for ongoing support, including sponsored in-person
training from their pharmacy chain and step-by-step
guidance from professional organizations. However, sev-
eral participants felt that they would benefit from add-
itional support, including updates on coverage available
for patients, lists of local prescribers, and algorithms or
summary sheets to “make sure certain points are dis-
cussed and we aren’t missing anything and everything is
documented properly” (010).
Anticipating that prescribers and pharmacists would
need additional technical support for initiating this new
practice, our research team was part of a national effort
to create a community of practice, the Canadian Abor-
tion Providers Support (CAPS) platform [35]. A few par-
ticipants noted in particular that registering with the
CAPS community, weekly online eye-catching bulletins,
and receiving monthly emailed updates from this website
provided them with ongoing support and information.
System readiness for mifepristone
Innovation-system fit
For some participants, there was a poor fit between
community pharmacy and mifepristone dispensing when
the initial restrictions were in place. As one participant
noted, the mandated training and the patient consent
form added time and expense to workflow: “It was very
challenging to start … because you almost had to go
through 50 hoops … It used to be that we had to give it
to [physicians] to give to [patients]. It was like it was
acid or something ... Mandated health professional train-
ing is no longer required. At the time, I had to get past a
test to be able to order it from [the manufacturer]”
(018). The initial regulation that physicians should dis-
pense the medication was perceived to be at odds with
scope of practice for the two professions. As one partici-
pant pointed out,
Physicians, I believe that they are more focused on
diagnosis and deciding what medication to use, but
when it comes to the medication itself, I think it’s
best to get it from the pharmacy, from a pharmacist,
because pharmacists, I believe that they are more
knowledgeable when it comes to medications (008).
Overall, participating pharmacists were either unaware
of the restrictions or did not find them to be an issue.
One person who was interviewed after all restrictions
were removed in November 2017 reflected on the early
days of mifepristone availability: “I know at that time not
every pharmacy was able to dispense it. You had to take
a course and register with the company and whatnot.
That was before they removed that barrier” (020).
Dedicated time and resources
Because counselling was perceived to be an important
component of the dispensing process, system readiness
for mifepristone was enhanced when the pharmacy had
a private counselling room that would allow for consul-
tations with patients. Participants had varying perspec-
tives about the cost of providing counselling, with a few
highlighting a need for this service to be reimbursed in
addition to the dispensing fee. The time when mifepris-
tone counselling was required was also a factor, with
some participants raising the concerns about whether
patients could be accommodated during peak hours.
However, others pointed out that the need for counsel-
ling was not unique to mifepristone and that the need to
triage patients during high-volume times was “just retail
pharmacy” (020). The tension between workload and
provision of care was articulated by one participant from
Quebec who explained the following:
In the pharmacy, sometimes we have many things
to do all at once, so we're really overloaded at times
and sometimes stressed. But we’re still going to take
the necessary time with someone for this type of
intervention … So, while it’s stressful when there's
something new, at the same time, it's not negative
either. (Q04)
Power balances (supporters vs. opponents)
A potential barrier to mifepristone uptake was difference
in support toward abortion care within pharmacy set-
tings, including conscientious objectors who opposed
implementation, and the relative power of the individ-
uals involved in making implementation decisions. The
majority of participants expressed pro-choice attitudes
but observed ethical objections to abortion care around
them, including among colleagues and in their commu-
nity. Only two participants expressed personal qualms
about the ethics of abortion, but they focused on their
professional responsibility to provide care saying, for
example,
I was really thinking about it. I was contemplating
about it for a long time before continuing the
course, but I was actually thinking the best probably
that I can give to the patient who has a prescription
for it would be full information of the product.
(008)
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Other participants described how even if their phar-
macy stocks and dispenses mifepristone, individual phar-
macists would have the ability to decline a patient’s
prescription. One participant illustrated how individual
pharmacists would have the power to oppose abortion
care:
There’s a couple of colleagues that are fairly reli-
gious … They wouldn’t be comfortable being in-
volved in that process as far as I’m aware. Then that
would be a little bit of a barrier, so if they were the only
one on the shift and the patient came to them, they
would have to send them to another pharmacy. (010)
Other participants also raised this possibility and
pointed to mitigating factors. They perceived, for in-
stance, that colleagues with anti-choice views were rare.
If a patient presented to an unsupportive pharmacist, it
was likely that another, supportive team member would
be available for the patient. This was exemplified by one
participant who described how one of four team mem-
bers refused to provide mifepristone,
She represents fifteen hours a week ... It's not a big
challenge to work with the limitations brought by
her conscientious objection to the dispensation of
the service, and besides, one works around her skills
and comforts to adjust. (Q03)
Notably, although almost all participants described
their professional communities as pro-choice, social
norms about abortion may have prevented some partici-
pants from establishing external collaboration. For ex-
ample, one participant from an Atlantic province
commented, “It’s not something that’s talked about a
lot” (014).
The only reported instance in which anti-choice atti-
tudes within a team significantly hindered adoption of
mifepristone was when management at an independent
pharmacy asked the team to come to a consensus about
whether or not to provide abortion medications:
I think our team views it as a risky subject because
it is not only the people who are receiving but also
the team providing it, if they have an ethical di-
lemma or they have a belief that we shouldn’t be
providing this … I was told that we all have to decide as
a team if this is ethical and comfortable for us. (002)
Diffusion and dissemination of mifepristone: “Help it
Happen”
Effective communication about mifepristone — what it
is, how to dispense it, and what federal restrictions were
in place — helped to spread information about medical
abortion among pharmacy practices in Canada. Partici-
pants’ experiences suggested that spread was primarily
through active dissemination, where communication was
planned through formal professional channels by
trusted, influential experts, and authorities.
Network structures
The diffusion and dissemination of mifepristone practice
was facilitated by two types of networks. Vertical net-
works with professional organizations and colleges dis-
seminated information about the easing of restrictive
measures and authoritative decisions, like announce-
ments of public coverage for the pill. Horizontal social
networks with peers and champions helped to spread in-
formation and supported mifepristone distribution as a
routine pharmacy practice. Both network structures
worked to normalize mifepristone as part of pharmacist
scope of practice.
Most participants described receiving links to educa-
tional material from professional organizations such as
the Canadian Pharmacists Association and provincial
College of Pharmacists as well as from their corporate
chain (e.g., e-bulletins or an on-site consultant). In
addition to raising awareness of the training programme
and other educational resources, these interactions
helped normalize the practice of dispensing mifepristone
even before the change in government regulations. As
one participant described,
My sense from [the College of Pharmacists] is that
they want you to do whatever is right for the patient
whether the monograph says it should go through
the pharmacy or not. I think they feel that the phar-
macists play a role in dispensing this product and
not just dispensing the product but taking care of
the patient. I think they would wholeheartedly sup-
port this going through where the patient gets pre-
scription. (001)
The effect of this communication on normalizing
abortion care as part of the pharmacy scope of practice
was very important for some participants. For example,
one pharmacist who was resistant to supporting abortion
for religious reasons remarked,
The moment I received an e-mail from [my profes-
sional organization], it made me feel that eventually
all pharmacists would be dispensing it, and all phar-
macists are obliged to at least be knowledgeable
about the product to help moms in case they would
have the prescriptions. (008)
Similarly, corporate offices were described as taking
steps to keep pharmacists up-to-date on regulatory
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changes and to make mifepristone a routine component
of policies and procedures. While this vertical network
communication was important for raising awareness and
acceptance of mifepristone dispensing, several partici-
pants commented that it was too infrequent or inaccess-
ible. As one participant pointed out, “A lot of the times,
you’ll learn stuff and start getting stuff, but if you don’t
kind of implement it or take initiative right away, things
don’t just happen” (009). This was echoed by another
participant, who said, “A one-time letter is not going to
make it happen. Like, I got this one letter from the col-
lege … it’s a lengthy letter. It’s huge. It’s not appealing
for people who only have a minute to read the e-mail”
(002). Receiving brief, regular updates thus appeared
vital to support implementation and routinization of the
pharmacy practice.
Champions external to the team who held regional
leadership roles also played a diffusion and dissemin-
ation role for some participants. For example, one par-
ticipant explained that “Dr. [name redacted] who is next
door, yeah, she’s played a big role moving this forward
and getting information out there for training with other
professionals, pharmacy or physicians, out there looking
for more information” (012).
In most cases, managers, pharmacists, and assistants
within teams initiated informal communication through
their horizontal peer networks about training opportun-
ities and had discussions about who on the team would
and would not be comfortable participating in abortion
care. Several participants also had or planned to reach
out to prescribers in the community to inform them that
mifepristone was available at their pharmacy. Examples
of passive communication were less common among
participants, but one participant was engaged in a Face-
book group for pharmacists that shared information
about mifepristone.
Implementation of mifepristone in pharmacy practice
External collaboration
Participants’ experiences suggest that communication
with prescribers was the most important factor for phar-
macists to decide whether to stock mifepristone in their
pharmacy dispensary. External collaboration depended
on whether local prescribers were aware of mifepristone
for medical abortion, willing to prescribe the medication,
and familiar with the community pharmacies in their
area that were stocking the medication. Some pharma-
cists had strong ongoing collaborative physician-
pharmacist relationships that supported seamless imple-
mentation. As one participant described,
A group of us – two pharmacists, the nurse practi-
tioner who works in the sexual office clinic, and a
couple of family doctors – we got together, talked
about how we were going to do it locally … I think
we’ve already helped quite a few women, and the
process has been – with a few little tweaks along
the way – it’s been very, very smooth. (004)
Pharmacists perceived that mifepristone medical abor-
tion might be complex for prescribers, infrequent in
their population, or incompatible with their values. For
example, one participant said,
I haven’t talked to any of the local physicians per-
sonally, but I don’t expect any of them would be un-
comfortable. That being said, I also think a lot of
them would refer. I think they’re comfortable with
the drug itself but perhaps uncomfortable prescrib-
ing, were I to wager a blind estimate just based on
their prescribing histories (015).
In some cases, sustainable implementation of mifepris-
tone depended on the prescriber being willing to send
patients to the participant’s pharmacy for mifepristone
prescriptions. One participant described reaching out to
a high-volume abortion provider to let them know about
the availability of mifepristone in that pharmacy. Ini-
tially, the participant described, “She and I had a great
working relationship because we figured out essentially
what information we gave to the patient, agreed upon
the process, what form she was going to give to the pa-
tients to bring to me, and also if there were any issues at
all, for me to communicate with her” (003). However,
when a pharmacy closer to this prescriber’s clinic began
to dispense mifepristone, the participant stopped receiv-
ing clients, reflecting, “I’ve sort of run out of options as
to how do I go about dispensing it or getting physicians
to actually send people this way” (003).
These collaborative partnerships were rare and the
dominant sentiment from participants was “physicians
don’t know that we can provide it … that’s why we
haven’t seen it yet” (009). These pharmacists described
having no or few conversations with prescribers about
mifepristone. They perceived that their experiences of
low consumer demand (i.e., few mifepristone prescrip-
tions received at the pharmacy) was due to prescriber
barriers such as lack of familiarity with mifepristone,
lack of awareness that primary care physicians and nurse
practitioners could provide medical abortion, and
perhaps an unwillingness to provide this care.
Interaction between domains and over time
The notion of time recently has been integrated into Dif-
fusion of Innovation models to account for the dynamic
changes that occur over an implementation journey, and
the concomitant need to adapt an innovation in re-
sponse to feedback [41]. The experiences of study
Munro et al. Implementation Science           (2021) 16:76 Page 9 of 13
participants indicate that relationship building and feed-
back over time, including integrated KT activities like
our CAPS community of practice, were a key facilitator
for mifepristone implementation. Soon after mifepris-
tone was made available in 2017, Health Canada quickly
updated the product label to enable usual and customary
pharmacist dispensing for this medication. This change
was one of the first made by federal decision makers in
their removal of restrictive measures. Participants per-
ceived it was communicated efficiently through phar-
macy licencing colleges and professional organizations.
Strong connections between pharmacists and their pro-
fessional and corporate organizations (vertical network
structures) supported prompt communication about
changing training requirements and Health Canada mea-
sures for dispensing of mifepristone. Over time, as the
innovation-system fit became more compatible, the chal-
lenge shifted from system readiness to adoption in prac-
tice, and lack of external collaboration became the
pressing issue. Weak interprofessional connections with
local prescribers meant pharmacists who intended to
practice had limited to no prescriptions arriving at their
pharmacy. Developing these collegial professional rela-
tionships where none had previously existed was a time-
consuming endeavour that required pharmacists to
become change agents. As one participant described, “I
called to let [the physician] know that, ‘You know what?
This is a new drug that just came out in the market. I
am one of the pharmacies’” (003).
Discussion
Our results suggest that pharmacists from across Canada
were willing and able to integrate medical abortion care
into their practice and those who had initiated this new
clinical practice area were satisfied with their ordering of
the medication and the dispensing and clinical counsel-
ling experiences. These results illustrate how the first
year of implementation of mifepristone medical abortion
was characterized by the uncertainty of changing re-
strictive measures and continuous reinvention through
self-organization to bring mifepristone dispensing in line
with usual practice. Our approach demonstrates how to
operationalize the Diffusion of Innovation framework in
the context of an integrated KT study and provides a
case example of how use of these complimentary
approaches may accelerate policy changes and facilitate
implementation of a pharmaceutical innovation.
Our thematic analysis indicated that several key
Diffusion of Innovation constructs impacted uptake of
mifepristone dispensing. Pharmacists perceived that
mifepristone would benefit their patients and, especially
after the removal of numerous initial Health Canada re-
strictions, felt that routine patient counselling was un-
likely to disrupt clinical practice. At an individual level,
pharmacists agreed that providing the gold standard
medical abortion treatment carried advantages relative
to off-label and surgical options. For most participants,
providing abortion care was also aligned with personal
pro-choice values or a professional commitment to pro-
viding well-informed care, although they sometimes per-
ceived unsupportive, anti-choice attitudes among other
professionals. Provision of mifepristone was facilitated in
workplaces where professional organizations, corporate
bodies, and influential individuals actively encouraged
implementation. Strong support from professional orga-
nizations and continuing education programmes posi-
tively impacted adoption of mifepristone in the
community pharmacy setting. Nevertheless, incorpor-
ation of mifepristone ordering, stocking, dispensing, and
counselling were contingent on the community pharma-
cists and store managers in each individual pharmacy
location developing collaborative relationships with
physicians and nurse practitioners able to prescribe the
medication and refer their patients to these specific
community pharmacy locations. This collegial relation-
ship between prescribers and community pharmacists
has the potential to ensure that the community phar-
macy maintains mifepristone supplies, and provides pa-
tients with the clinical counselling and support that they
require.
Our results also suggest that relationship building and
feedback — a “help it happen” approach to Diffusion of
Innovation — were key facilitators for mifepristone im-
plementation. Throughout the first year of mifepristone
availability, our research team engaged in sensemaking
with stakeholders from Health Canada, sharing real-time
data from the present study. In turn, Health Canada up-
dated the product label to enable pharmacists to dis-
pense the medication, making it consistent with their
usual practice [23, 25]. Pharmacy licencing colleges and
professional organizations then communicated these
changes to their members, our participants. Our ap-
proach demonstrates how integrated KT and Diffusion
of Innovation may work together as complimentary
frameworks to facilitate uptake of evidence-based inter-
ventions in routine practice.
Our findings will also be relevant to researchers in-
volved in large-scale implementation research involving
abortion or similarly stigmatized health services. Since
there are no legal restrictions on abortion in Canada and
restrictions on mifepristone were removed by the Can-
adian regulatory body in the course of our study, policy
barriers had minimal impact on Canadian pharmacists.
In the USA, where federal policies are a persistent bar-
rier to pharmacist dispensing, retail pharmacists support
the removal of restrictions on dispensing mifepristone
[3, 42, 43]. These attitudes are consistent with Australian
research in which pharmacists dispensing mifepristone
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felt it was within their routine practice [44]. Previous re-
search has shown that mifepristone dispensed outside of
hospitals, clinics, and medical offices is safe and accept-
able to both patients and prescribers [13, 45, 46]. Our
dual framework approach, bridging integrated KT with
the Diffusion of Innovation framework may be a helpful
model for other health care systems. In Australia, our
approach is being used and tested through the Aus-
CAPPS Network (The Australian Contraception and
Abortion Primary Care Practitioner Support), a commu-
nity of practice that supports the primary care workforce
to deliver evidence-based abortion and contraception
care, and feedback real-world practice experiences to
policy makers to facilitate practice support [47].
We offer a theory-driven, process-oriented, participatory
case study of the Canadian pharmacist experience. One
strength of our approach is that data collection took place
during the period of 2017 when restrictions on mifepristone
were removed. Our study also is strengthened by the inclu-
sion of pharmacy knowledge users in integrated KT, who
helped ensure the relevance of the work to pharmacy policy
and practice. Our use of Diffusion of Innovation to frame
the research facilitated a theory-driven approach and
allowed us to explore links between implementation con-
structs that have been investigated in previous studies. The
applicability of the results may be limited by the inclusion
of only participants who intended to stock mifepristone.
This sample was likely more aware of and open to their po-
tential role in providing the medication and were predom-
inantly pro-choice. Similarly, our findings should be
cautiously applied to other national contexts where Diffu-
sion of Innovation constructs may interact differently to
affect the implementation of mifepristone in primary care.
Conclusion
The evidence resulting from the Canadian experience
can inform the expansion of safe abortion services
through task sharing in other highly regulated settings.
We illustrate how pharmacists, as highly qualified and
accessible health care professionals, can be willing and
capable partners in this care, especially when strong
interdisciplinary collaborations are in place. Our study
demonstrates how to use integrated KT to operationalize
Diffusion of Innovation theory for complex, stigmatized
implementation challenges, like abortion care.
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